keyword
MENU ▼
Read by QxMD icon Read
search

rosuvastatin diabet

keyword
https://www.readbyqxmd.com/read/28416099/statin-use-and-risk-of-new-onset-diabetes-a-meta-analysis-of-observational-studies
#1
M Casula, F Mozzanica, L Scotti, E Tragni, A Pirillo, G Corrao, A L Catapano
BACKGROUND AND AIMS: Meta-analyses of randomized control trials investigating the association between incident diabetes and statin use showed an increased risk of new-onset diabetes (NOD) from 9% to 13% associated with statins. However, short follow-up period, unpowered sample size, and lack of pre-specified diagnostic criteria for diabetes detection could be responsible of an underestimation of this risk. We conducted a meta-analysis of published observational studies to evaluate the association between statins use and risk of NOD...
March 10, 2017: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/28406125/effect-of-rosuvastatin-on-dyslipidemia-and-other-parameters-associated-with-metabolic-syndrome-in-saudi-patients
#2
M M Rafeeq, H S Habib, Has Murad, M A Gari, Z J Gazzaz
CONTEXT: Metabolic syndrome (MS) is a constellation of metabolic irregularities consisting of dyslipidemia, hypertension, hyperglycemia, chronic inflammatory, and hypercoagulable state predisposing to diabetes and cardiovascular events. Statins are first-line drugs to treat the associated atherogenic dyslipidemia. AIM: Effect of rosuvastatin on MS in Saudi patients was studied. SETTINGS AND DESIGN: Prospective, open label, randomized clinical study...
April 2017: Nigerian Journal of Clinical Practice
https://www.readbyqxmd.com/read/28357773/centralized-pan-middle-east-survey-on-the-under-treatment-of-hypercholesterolemia-results-from-the-cepheus-ii-study-in-egypt
#3
Ashraf Reda, Alaa Etman, Ali Abdel-Rahim, Nabil Farag, Osama Sanad, Sameh Salamah
INTRODUCTION: As part of the CEPHEUS study, CEPHEUS I was conducted in 2010 and 2011 in Cairo and then the CEPHEUS II study was carried out in Alexandria and Delta Regions in Egypt between April 2014 and August 2015 to determine the proportion of dyslipidemic patients on lipid-lowering treatment reaching LDL-C treatment goals. METHODS: We conducted an open-label, observational, multicenter, cross-sectional survey where 90 investigators enrolled 1127 patients receiving lipid-lowering drugs for at least 3 months...
March 29, 2017: Cardiology and Therapy
https://www.readbyqxmd.com/read/28277855/using-lower-cost-statins-improves-outcomes-for-normal-cholesterol-non-diabetic-patients
#4
Ronen Arbel, Dan Greenberg
BACKGROUND The American College of Cardiology recommends considering initiation of cholesterol-lowering therapy in normal cholesterol adults aged 45-70, who are either diabetic or have a 10 year atherosclerotic cardiovascular disease higher than 7.5%. Although this policy was shown to be cost-effective, the multi-billion dollar budget impact may limit the adoption, diffusion and overall clinical impact of this therapy. OBJECTIVES We examined whether using a substantially lower cost statin (Simvastatin) in a much wider population, while accepting almost-as-good per-patient outcomes can provide better outcomes for the entire intended use population (IUP) under a pre-specified budget constraint...
February 21, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28260863/pharmacokinetic-interactions-between-glimepiride-and-rosuvastatin-in-healthy-korean-subjects-does-the-slco1b1-or-cyp2c9-genetic-polymorphism-affect-these-drug-interactions
#5
Choon Ok Kim, Eun Sil Oh, Hohyun Kim, Min Soo Park
To improve cardiovascular outcomes, dyslipidemia in patients with diabetes needs to be treated. Thus, these patients are likely to take glimepiride and rosuvastatin concomitantly. Therefore, this study aimed to evaluate the pharmacokinetic (PK) interactions between these two drugs in healthy males and to explore the effect of SLCO1B1 and CYP2C9 polymorphisms on their interactions in two randomized, open-label crossover studies. Glimepiride was studied in part 1 and rosuvastatin in part 2. Twenty-four participants were randomly assigned to each part...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28155189/diabetes-secondary-to-treatment-with-statins
#6
REVIEW
Markku Laakso, Johanna Kuusisto
PURPOSE OF REVIEW: This review summarizes the recent population-based studies, clinical trials, clinical metabolic studies, and genetic studies reporting the effects of statin therapy on the risk of diabetes. Recent studies aiming to explain the mechanisms how statin treatment affects insulin sensitivity and insulin secretion are also reviewed. RECENT FINDINGS: Statin therapy increases the risk of diabetes by 9%-12% in the two meta-analyses of statin trials and by 18%-99% in five population-based studies...
February 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/28029012/efficacy-of-moderate-intensity-statins-in-the-treatment-of-dyslipidemia-in-korean-patients-with-type-2-diabetes-mellitus
#7
Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon
BACKGROUND: There has been evidences of ethnic differences in the low density lipoprotein cholesterol (LDL-C) lowering effect of statin. We aimed to evaluate the efficacy of moderate-intensity statins in the treatment of dyslipidemia among Korean patients with type 2 diabetes mellitus (T2DM). METHODS: We analyzed a retrospective cohort that consisted of Korean patients with T2DM aged 40 to 75 years who had been prescribed any of the moderate-intensity statins (atorvastatin 10 or 20 mg, rosuvastatin 5 or 10 mg, pitavastatin 2 mg, or pravastatin 40 mg)...
February 2017: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/28025996/rosuvastatin-as-a-potential-preventive-drug-for-the-development-of-hepatocellular-carcinoma-associated-with-non-alcoholic-fatty-liver-disease-in-mice
#8
Keisuke Yokohama, Shinya Fukunishi, Masaaki Ii, Ken Nakamura, Hideko Ohama, Yusuke Tsuchimoto, Akira Asai, Yasuhiro Tsuda, Kazuhide Higuchi
Hepatocellular carcinoma (HCC) represents approximately 85% of all primary liver cancer cases. Non-alcoholic fatty liver disease (NAFLD) is one of the risk factors for HCC. NAFLD occurs in patients with components of metabolic syndrome, such as type 2 diabetes mellitus, obesity, hypertension and hyperlipidemia. Therefore, hyperlipidemia also represents a patient population at risk for HCC that can readily be identified. Rosuvastatin, a 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor, has exhibited a more potent affinity for the active site of HMG-CoA reductase than other statins...
November 2016: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/27872642/rationale-and-design-of-rnafh-study-effect-of-rosuvastatin-10%C3%A2-mg-d-on-nonalcoholic-fatty-liver-in-metabolic-syndrome-patients-without-overt-diabetes-evaluated-by-1-h-magnetic-resonance-spectroscopy
#9
Fan Ping, Xuan Wang, Jing Yang, Mei-Cen Zhou, Wei Li, Ling-Ling Xu, Yu-Xiu Li
Objective. The RNAFH study (effect of rosuvastatin on nonalcoholic fatty liver disease in metabolic syndrome patients without overt diabetes evaluated by (1)H-MRS) is a prospective randomized, single-center, open-label trail designed to assess the effect of rosuvastatin on the intrahepatocellular lipid (IHCL) level of nonalcoholic fatty liver disease (NAFLD). Methods. 40 NAFLD patients meeting inclusion and exclusion criteria with metabolic syndrome (MS) but without overt diabetes mellitus will be included...
2016: International Journal of Endocrinology
https://www.readbyqxmd.com/read/27861386/statins-and-risk-for-new-onset-diabetes-mellitus-a-real-world-cohort-study-using-a-clinical-research-database
#10
Dukyong Yoon, Seung Soo Sheen, Sukhyang Lee, Yong Jun Choi, Rae Woong Park, Hong-Seok Lim
Although concern regarding the increased risk for new-onset diabetes mellitus (NODM) after statin treatment has been raised, there has been a lack of evidence in real-world clinical practice, particularly in East Asians. We investigated whether statin use is associated with risk for NODM in Koreans. We conducted a retrospective cohort study using the clinical research database from electronic health records. The study cohort consisted of 8265 statin-exposed and 33,060 matched nonexposed patients between January 1996 and August 2013...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27830382/ticagrelor-and-rosuvastatin-have-additive-cardioprotective-effects-via-adenosine
#11
Yochai Birnbaum, Gilad D Birnbaum, Itamar Birnbaum, Sven Nylander, Yumei Ye
BACKGROUND: Ticagrelor inhibits the equilibrative-nucleoside-transporter-1 and thereby, adenosine cell re-uptake. Ticagrelor limits infarct size (IS) in non-diabetic rats and the effect is adenosine-dependent. Statins, via ecto-5'-nucleotidase activation, also increase adenosine levels and limit IS. HYPOTHESIS: Ticagrelor and rosuvastatin have additive effects on myocardial adenosine levels, and therefore, on IS and post-reperfusion activation of the NLRP3-inflammasome...
December 2016: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/27798199/predictors-of-atherosclerotic-events-in-patients-on-haemodialysis-post-hoc-analyses-from-the-aurora-study
#12
Marit D Solbu, Geir Mjøen, Patrick B Mark, Hallvard Holdaas, Bengt Fellström, Roland E Schmieder, Faiez Zannad, William G Herrington, Alan G Jardine
BACKGROUND: Patients on haemodialysis (HD) are at high risk for cardiovascular events, but heart failure and sudden death are more common than atherosclerotic events. The A Study to Evaluate the Use of Rosuvastatinin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA) trial was designed to assess the effect of rosuvastatin on myocardial infarction and death from any cardiac cause in 2773 HD patients. We studied predictors of the atherosclerotic cardiovascular events in AURORA...
October 17, 2016: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/27698930/statins-dose-dependently-exert-significant-chemopreventive-effects-against-various-cancers-in-chronic-obstructive-pulmonary-disease-patients-a-population-based-cohort-study
#13
Chun-Chao Chen, Yi-Ping Hsu, Ju-Chi Liu, Pai-Feng Kao, Li-Chin Sung, Chao-Feng Lin, Wen-Rui Hao, Shing-Hwa Liu, Szu-Yuan Wu
PURPOSE: Chronic obstructive pulmonary disease (COPD) is associated with an increased cancer risk. We evaluated the chemopreventive effect of statins against all cancers in COPD patients and identified the statin with the strongest chemopreventive effect. PATIENTS AND METHODS: All patients diagnosed with COPD at health care facilities in Taiwan (n = 116,017) from January 1, 2001, to December 31, 2012, were recruited. Each patient was followed to assess the following protective and risk factors for all cancers: age; sex; comorbidities (diabetes, hypertension, dyslipidemia) and the Charlson comorbidity index [CCI]); urbanization level; monthly income; and nonstatin drug use...
2016: Journal of Cancer
https://www.readbyqxmd.com/read/27652354/do-statins-really-cause-diabetes-a-meta-analysis-of-major-randomized-controlled-clinical-trials
#14
Alaa J Rahal, Ahmed I ElMallah, Rita J Poushuju, Rana Itani
OBJECTIVES: To investigate and establish the relationship between the use of statin therapy and the risk of development of diabetes.  METHODS: PubMed and the Cochrane Central Register of Controlled Trials was searched for randomized controlled end-point trials of statins, with more than 1000 subjects and a minimum of one-year follow-up period, published until August 2015. The odds ratio (OR) of diabetes incidence with overall statin therapy as well as with different statins in question was calculated through random effect meta-analysis model...
October 2016: Saudi Medical Journal
https://www.readbyqxmd.com/read/27648292/evaluation-of-statin-prescriptions-in-type-2-diabetes-india-heart-watch-2
#15
Rajeev Gupta, Sailesh Lodha, Krishna K Sharma, Surendra K Sharma, Sunil Gupta, Arthur J Asirvatham, Bhupendra N Mahanta, Anuj Maheshwari, Dinesh C Sharma, Anand S Meenawat, Raghubir S Khedar
BACKGROUND: Contemporary treatment guidelines advise statin use in all patients with diabetes for reducing coronary risk. Use of statins in patients with type 2 diabetes has not been reported from India. METHODS: We performed a multisite (n=9) registry-based study among internists (n=3), diabetologists (n=3), and endocrinologists (n=3) across India to determine prescriptions of statins in patients with type 2 diabetes. Demographic and clinical details were obtained and prescriptions were audited for various medications with a focus on statins...
2016: BMJ Open Diabetes Research & Care
https://www.readbyqxmd.com/read/27646783/characterization-and-cholesterol-management-in-patients-with-cardiovascular-events-and-or-type-2-diabetes-in-the-netherlands
#16
Edith Heintjes, Josephina Kuiper, Bianca Lucius, Fernie Penning-van Beest, Lucie Kutikova, Anho Liem, Ron Herings
OBJECTIVE: To describe clinical characteristics and cholesterol management of patients with cardiovascular events (CVEs) and/or type 2 diabetes mellitus (T2DM) with high low-density lipoprotein cholesterol (LDL-C) > 1.8 mmol/L in the Netherlands. RESEARCH DESIGN AND METHODS: From the PHARMO Database Network a cross-sectional cohort was constructed. The descriptive study included patients on lipid modifying therapy (LMT) in 2009, classified as high cardiovascular risk based on a history of T2DM or CVE, with 2010 LDL-C levels above 1...
January 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27623996/review-of-pharmacokinetic-data-of-different-drug-classes-in-goto-kakizaki-rats-a-non-obese-model-for-type-2-diabetes-mellitus-case-studies-and-perspectives
#17
Harilal Patel, Poonam Giri, Nuggehally R Srinivas
Goto-Kakizaki (GK) rats represent a unique non-obese and lean model with manifestation of type 2 diabetes (T2DM) broadly mimicking the human T2DM development. Therefore, in addition to the use of GK rats to test the efficacy of drugs, it may represent a great tool to study the influence of altered physiological process and/or organ specific pathophysiological changes (i.e., liver, kidney, etc.) on the disposition of drugs. The objectives of the review were: (a) to compile the published pharmacokinetic data of several drugs, such as cephalexin, cyclosporine, exendin-4, gliclazide, grepafloxacin, rosuvastatin, salsalate, salicylic acid, and theophylline, in GK rats relative to normal rats; and (b) critically evaluate the possible role of physiologically altered processes on the pharmacokinetics of reviewed drugs...
September 13, 2016: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/27565724/atorvastatin-and-rosuvastatin-improve-physiological-parameters-and-alleviate-immune-dysfunction-in-metabolic-disorders
#18
Sungwon Lee, Youngjoo Lee, Jiyeon Kim, Jinho An, Kwanghee Kim, Heetae Lee, Hyunseok Kong, Youngcheon Song, Kyungjae Kim
This study was designed to characterize the potential therapeutic effects of two statin drugs commonly used to treat dyslipidemia in inflammation-linked metabolic disorders related to type 2 diabetes. Atorvastatin (10 mg/kg/day) and rosuvastatin (3 mg/kg/day) were administered to mice with diet-induced obesity (DIO). The statins lowered serum total and LDL cholesterol levels, and improved the atherogenic index and cardiac risk index. Furthermore, the drugs decreased fasting glucose levels, improved glucose tolerance, and decreased fat tissue weight and adipocyte size; this was accompanied by an overall body weight loss tendency...
September 23, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27544612/rosuvastatin-dose-dependently-improves-flow-mediated-dilation-but-reduces-adiponectin-levels-and-insulin-sensitivity-in-hypercholesterolemic-patients
#19
Kwang Kon Koh, Pyung Chun Oh, Ichiro Sakuma, Yonghee Lee, Seung Hwan Han, Eak Kyun Shin
BACKGROUND: Genetic analysis from patients participated in the randomized trials reported that the increased risk of type 2 diabetes noted with statins is at least partially explained by HMG-coenzyme A reductase inhibition. We investigated vascular and metabolic phenotypes of different dosages of rosuvastatin in hypercholesterolemic patients. METHODS: A randomized, single-blind, placebo-controlled, parallel study was conducted in 48 patients on placebo, and in 47, 48, and 47 patients given daily rosuvastatin 5, 10, and 20mg, respectively during a 2month treatment period...
November 15, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27541380/the-impact-of-rosuvastatin-on-the-density-score-of-coronary-artery-calcification-in-coronary-artery-disease-patients-with-type-2-diabetes-mellitus-rationale-and-design-of-roscal-study
#20
Wenbin Zhang, Yi Luan, Chongying Jin, Shengjie Xu, Xukun Bi, Yanbo Zhao, Fuyu Qiu, Guosheng Fu, Min Wang
INTRODUCTION: More and more evidence suggests that the density of calcification plays an important role in the plaque stability. However, few studies have investigated the statin treatment on the density of plaque calcification in patients with both coronary artery disease (CAD) and type 2 diabetes mellitus. METHODS: One hundred and twenty-two CAD patients with type 2 diabetes with confirmed coronary artery calcification (CAC) will be recruited consecutively in a 12-month period...
December 2016: Clinical Drug Investigation
keyword
keyword
117897
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"